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Abstract 
Mosquitoes and ticks can transmit viruses to humans. They can be either direct vectors 
without any intermediate host (as is the case for mosquitoes) or have an intermediate host 
(as is the case for ticks). 
In recent years, due to global temperature changes, two phenomena have been observed i) 
the migration of mosquitoes to places that have become warmer, enabling them to adapt to 
new niches and spread to new areas, and ii) the ability to better survive in different 
seasons. The increasing incidence of warm winters favours better conditions for mosquitoes 
and ticks. This increases the exposure of humans to virus infection, especially in urban 
areas1,2. 
The viruses that cause Zika (ZIK), Dengue (DEN), Chikungunya (CHIK) and tick-borne 
encephalitis (TBE) belong to the same virus family. ZIK, DEN and CHIK are transmitted by 
mosquitoes, and TBE is transmitted by ticks. Mosquitoes are responsible for the spread of 
human diseases such as Dengue fever, Chikungunya and some neurological disorders, while 
ticks are responsible for the spread of encephalitis. Once infected with the virus, the most 
common symptoms are usually mild and characterised by fever, skin rash, joint pains and 
conjunctivitis. In May 2015, an outbreak of Zika virus (ZIKV) infection occurred in Brazil 
with an estimated total of  up to 1.3 million of ZIKV infection cases. This event caught the 
attention of scientists, the media and the public, and raised awareness of the risk of 
underestimating mosquito-carried disease and the need to mitigate the spread of the virus 
by operating at multiple levels (i.e. developing vaccines, mapping the distribution of 
mosquitoes, and controlling their habitats).  
This report provides the public with four pillars of information. The first (chapters 1-3) gives 
general information about the vectors, viruses and the detection methods, and the second 
(chapter 4) gives the most recent literature data about their distribution, particularly in 
Europe. The third (chapter 5) is mainly focused on ZIKV, and compares the recent extensive 
media attention given to this with the scientific results, in order to avoid the spread of fake 
news (incorrect scientific news). Finally, the fourth pillar (chapter 6) describes mosquito 
control strategies, which includes several tactics for limiting the spread of mosquitoes and 
monitoring their habitats.   
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1 JRC role in fighting water-borne diseases  
The exploratory project “Molecular biosensors & climate data for crisis management to 
prevent waterborne microorganism impact” (Biocli4crisma), which started in 2015, is 
coordinated by several Directorates of the Joint Research Centre (JRC)†. 
This project aims to link the detection of waterborne microorganisms with climate data, to 
ultimately produce a predictive model that can be used for crisis mitigation and 
management. Biocli4crisma covers climate change impact events, including: i) an increase 
in episodes of Harmful Algal and Cyanobacterial Blooms (HABs); ii) the impact of storms 
and floods on public health; iii) the vulnerability of European regions to tropical arboviruses 
(arthropod-borne viruses).    
Collaboration with European and national agencies would allow for the development and 
regular updating of a predictive model of the spread of arboviruses, which could become a 
precautionary system similar to the European Flood Awareness System (EFAS)‡. 
The project focuses on detecting the vector-borne Dengue virus (DENV), Chikungunya virus 
(CHIKV) and Zika virus (ZIKV) in environmental samples to determine their presence and 
distribution in Europe.  
These three viruses belong to the arbovirus family and are carried by different species of 
Aedes mosquitoes. Since the transmission of the arbovirus to the offspring of mosquitoes 
has already been reported3,4, the JRC intends to perform field campaigns to collect 
mosquitoes in all developmental stages (i.e. the egg, larvae, pupa and adult stages). The 
field campaigns would allow us to map the distribution of the pathogen-carrying mosquito, 
and to evaluate the mosquito biomass and the potential risk to the population. 
The present report aims to raise public awareness of the threat posed by arboviruses, with a 
focus on the most recently emerging arbovirus, ZIKV. 
 
                                                          
† Accessible from https://ec.europa.eu/jrc/en.  
‡ https://www.efas.eu/  
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2 Mosquito: a transmission vector 
Several viral diseases are transmitted to humans through arthropods such as mosquitoes 
and ticks. Viruses that infect both arthropods and vertebrates are generally classified as 
arthropod-borne viruses (arboviruses), and include Dengue (DENV), Chikungunya 
(CHIKV) and Zika (ZIKV) viruses (Figure 1).  
In mosquitoes, arboviruses have the ability to infect the midgut epithelial cells and other 
tissues, including the salivary glands. To be transmitted to humans and animals, viruses 
must replicate in the salivary glands and be expelled through the saliva to the blood (Figure 
2)5,6.   
 
 
Figure 1. Arbovirus transmission cycle (Source: JRC) 
Most arboviruses are transmitted to vertebrates (primarily primates, birds, small mammals) 
and arthropods in a sylvatic (wild) cycle involving different species of Aedes mosquitoes. In 
suburban and urban settings, infected Aedes mosquitoes (primary Aedes aegypti and Aedes 
albopictus) spread the virus through a human–mosquito–human cycle, which means that 
the virus can be acquired by mosquitoes from an infected person and then transmitted to 
other humans. 
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Figure 2. Transmission of arboviruses via mosquito bites (Source: JRC) 
 
Aedes mosquitoes usually proliferate in tropical areas with moderate precipitation, humidity 
and warm temperatures. Populated urban areas provide optimal conditions for the spread of 
some species such as Aedes aegypti and Aedes albopictus7,8. In a study conducted in 
southern Mexico, where Dengue (DEN) is endemic, the authors identified two peaks of 
activity for mosquitoes in the diurnal activity of both Aedes aegypti and Aedes albopictus in 
the sylvan (wild) environment: one in the morning and another in the afternoon. By 
contrast, no differences were found in domestic areas, where the level of activity remained 
relatively constant throughout the day9. It is well known that the activity of mosquitoes is 
influenced by different factors, including temperature and light, and these additional 
observations suggest that some environmental conditions (host availability, time of day) can 
modify mosquito behaviour10,11. Light is a key element which influences the intrinsic factors 
responsible for the cyclical oviposition of the Aedes species12.  
All mosquitoes develop through four instar stages during their life cycle: egg, larva, pupa 
and adult (Figure 3). The first three stages develop in water. Eggs laid in water hatch into 
larvae, which subsequently metamorphose into pupae. After a mosquito is fully developed, 
it emerges as an adult from the pupa stage13. The adult mosquito can survive 30 to 40 days 
in natural habitats, while in laboratory conditions it can survive up to 117 days14. 
Only female mosquitoes bite humans and other animals. They suck blood in order to obtain 
the protein and iron needed for egg development. Mosquito eggs are usually laid in water 
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that contains a moderate amount of organic matter and in vessels such as plant pots, 
barrels and tyres. Dark water reservoirs with low salinity levels are preferential breeding 
sites for both Aedes aegypti and Aedes albopictus mosquitoes12. These two species have 
been widely studied since they are vectors for several arboviruses, including DENV, CHIKV 
and ZIKV15,16. They have been in Africa and Asia for decades, and have more recently 
become established in some European countries and the Americas. Arboviruses constitute a 
relevant public health problem, in particular because their presence is becoming more and 
more established worldwide17. While different strategies that target the reduction of 
population density are currently under investigation, mosquitoes are difficult to eradicate as 
females can lay sticky eggs in different places, and the larvae can survive for months18. 
Mosquito eggs can also resist suboptimal conditions, such as low humidity and temperature 
levels (Figure 3)19-21. 
 
Figure 3. Mosquito life cycle (Source: JRC) 
The adult female mosquitoes release their eggs in water where larvae develop. Mature 
larvae turn into pupae and then become adults. The duration of each developmental stage 
may vary depending on the environmental conditions. Eggs can take from 3 to 13 days to 
hatch, larvae mature within 5 to 20 days and pupae may take between 1 and 7 days to 
metamorphose into adult mosquitoes. Adult Aedes mosquitoes can survive up to 117 days. 
Oviposition is dependent on protein and iron sources, which are acquired through blood 
meals. In periods of dehydration or eminent decrease in temperature, the laid eggs are 
slightly different, and can survive under extreme situations. The resistant eggs will hatch 
once optimal conditions for development are present. Larvae can also survive for months20. 
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3 Pathogenic arboviruses 
An arbovirus is a virus transmitted by blood-feeding arthropods such as mosquitoes, sand 
flies, ticks or gnats. The term arbovirus comprises viruses from different families (see Figure 
4 and Table 1).  
During the past twenty years, several arboviruses have been considered as emergent 
disease agents, and are now deemed to be serious public health concerns17. Dengue virus 
(DENV) and Chikungunya virus (CHIKV) are considered to be among the most prevalent 
arboviruses worldwide.  
 
 
 
 
Figure 4. Arbovirus families (Source: JRC) 
The figure shows the five different arbovirus families that cause human encephalitis, and 
some of the most famous viruses belonging to each family. 
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Table 1. List of pathogenic arbovirus families with examples of the viruses and their 
transmission cycles (vector and hosts)22-25.  
Virus family 
Virus 
genus 
Example 
Virus 
type 
Host Vector 
Intermediate 
host 
Flaviviridae Flavivirus 
Dengue virus RNA Human Aedes n/a 
Zika virus RNA 
Human 
Monkey 
Aedes n/a 
West Nile virus RNA 
Equine 
Human 
Culex Birds 
Tick-borne 
encephalitis 
RNA 
Human; 
Wild animals 
(hares, roe 
deer, foxes, 
boar, birds) 
Tick 
Small wild 
rodents, 
but also 
insectivores 
and carnivores 
Japanese 
encephalitis 
virus 
RNA 
Equine 
Human 
Culex 
Birds 
Swine 
Yellow fever 
virus 
RNA 
Human 
Monkey 
Aedes n/a 
Togaviridae Alphavirus 
Venezuelan 
equine 
encephalitis 
virus 
RNA 
Equine 
Human 
Culex 
Aedes 
Psorophora 
Rodents 
Chikungunya 
virus 
RNA Human Aedes n/a 
Bunyaviridae 
Nairovirus 
Crimean-Congo 
haemorrhagic 
fever virus 
RNA Human tick n/a 
Phlebovirus 
Rift Valley fever 
virus 
RNA Sheep, Cattle Aedes Ruminants 
Reoviridae Orbivirus 
Bluetongue 
virus 
RNA Ruminants Culicoides Cattle 
Orthomyxoviridae Thogotovirus Bourbon virus RNA Human Tick Swine 
RNA: ribonucleic acid 
n/a: Not applicable 
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3.1 Dengue virus 
 
Dengue virus (DENV) is responsible for Dengue (DEN) and its severe form, Dengue 
Haemorrhagic Fever (DHF). It can be caused by five different serotypes: DENV-1, DENV-2, 
DENV-3, DENV-4 and DENV-526. They are usually transmitted in urban and densely 
populated areas by the Aedes species found in tropical and subtropical regions, primarily 
Aedes aegypti, but also Aedes albopictus. DEN is endemic in more than 100 countries, 
particularly in Africa, the Americas, South East Asia, Eastern Mediterranean regions and the 
Western Pacific. Cases of Dengue have been documented in Buenos Aires, south-eastern 
France, Hong Kong, Madeira, Pakistan and Yemen27,28. The transportation of goods, 
globalisation, travel and migration have helped spread the virus and vectors to different 
parts of the world (Figure 5). The incidence of the disease is estimated to be 50 million 
infections per year worldwide, with 90% of the cases of the most severe form of the 
disease, DHF, reported in children of less than five years of age29. The febrile phase lasts for 
3 to 7 days, and most patients recover with no major complications. DHF occurs after a 
secondary infection with a different serotype or multiple infections with other serotypes. 
Patients with DHF show symptoms of severe thrombocytopenia, plasma leakage and 
haemorrhagic manifestations30,31. Untreated, the disease may lead to severe complications 
and can even be fatal32. There are no specific antiviral agents to treat Dengue infections in 
humans, and there is no licensed vaccine to prevent the disease33,34. Treatment is based on 
supportive therapy using fluid replacement and platelet transfusion (where there is a rapid 
decrease in platelet count). Better control of mosquito transmission, the development of a 
vaccine and increased efforts to produce antiviral and therapeutic drugs are needed in order 
to reduce Dengue infections. 
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Figure 5. Global distribution of alerts of Dengue virus (DENV) in the past 3 months (August-
November 2017) 
The large circles indicate a country-level alert, while state, province and local alerts are 
indicated by the small circles. Marker colour reflects the importance of events at a particular 
location during a given time window. An event's degree of importance is based on the 
significance rating of the alert provided by HealthMap users.§  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                          
§ Data source: http://www.healthmap.org/, last accessed on 13/11/2017. 
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3.2 Chikungunya virus 
 
Chikungunya virus (CHIKV) is an alphavirus that causes Chikungunya (CHIK), a severe 
illness with symptoms similar to those of Dengue virus (DENV), which can lead to its 
misdiagnosis and underestimations of its frequency. The clinical picture that characterises 
CHIK is a notable presence of acute arthritis and severe joint pains35,36. CHIKV is associated 
with low mortality rates37.  
The first outbreak of CHIK was reported in Tanzania in July 195238. At present, three 
genotypes of CHIKV have been identified: West African, East/Central/South African (ECSA) 
and Asian39. Following its first isolation, CHIKV has been detected in India and Southeast 
Africa. Since 2004, the virus has spread to many other countries, including Kenya, Italy, 
France and, more recently, Spain (Figure 6)40,41.  
CHIKV is primarily transmitted by the tropical and subtropical mosquito Aedes aegypti, but a 
CHIKV variant, characterised by mutations in the genes encoding envelope glycoproteins, is 
preferentially transmitted by Aedes albopictus mosquitoes42. The first European CHIK 
outbreak reported in Italy was caused by this ECSA variant, whose adaptation to the new 
vector Aedes albopictus likely contributed to the diffusion of CHIK in temperate climates and 
in rural habitats where Aedes aegypti mosquitoes are less common43.  
In October 2013, CHIKV was detected on the island of Saint Martin (Caribbean Sea). The 
viral strain involved in spreading the infection belonged to the Asian genotype that 
subsequently expanded its geographic range to circulate in the Caribbean, Central America, 
northern South America and, more recently, Florida44,45.  
These recent findings about the spread of CHIKV underline the possibility that the viruses 
may hit not only tropical and subtropical zones but also temperate regions. CHIK infections 
arise from a human-mosquito-human cycle (Figure 1). Unfortunately, specific therapies or 
vaccines against CHIKV infection are not yet available, although many studies are 
addressing these issues36,44. Treatment is supportive and includes increased fluid intake and 
the use of medicines to relieve pain (anti-inflammatory drugs and immunomodulators)36,44.  
The spread of CHIK in recent years highlights the need for more efficient mosquito control 
programmes and better characterisation of the CHIKV biology for therapy purposes. Looking 
at Europe, on September 2017, the Italian Ministry of Health confirmed nine cases of 
CHIKV, three in the city of Anzio (Lazio region) and six in the capital city of Rome, Lazio. As 
of the first week of October, 146 out of a total of 239 confirmed cases had been reported in 
the Lazio region, and six cases had been confirmed in the city of Guardavalle Marina, in 
Calabria region46. There have been additional CHIK cases in other Italian regions including 
Le Marche, Emilia-Romagna and Lombardy, as well as in other European countries including 
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France and Germany46,47. Italy experienced the first outbreak of autochthonous 
Chikungunya in the Emilia-Romagna region in 2007. France was the only other European 
country to have reported CHIKV outbreaks, in 2010 and 201448,49. 
  
 
 
Figure 6. Global distribution of alerts of Chikungunya virus (CHIKV) in the past 6 months 
(May-November 2017) 
The large circles indicate a country-level alert, while state, province and local alerts are 
indicated by the small circles. Marker colour reflects the importance of events at a particular 
location during a given time window. An event's degree of importance is based on the 
significance rating of the alert provided by HealthMap users.** 
 
                                                          
** Data source: http://www.healthmap.org/, last accessed on 13/11/2017. 
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3.3 Zika virus 
 
Zika virus (ZIKV) is an arbovirus belonging to the same family as Dengue virus (DENV). 
Until recently, the few ZIKV infections that were reported were always associated with mild 
symptoms, similar to flu symptoms and skin rash, which spontaneously disappeared within 
a week50. Zika (ZIK) infection can be asymptomatic and, unlike Dengue (DEN), is associated 
with conjunctivitis51. This virus has been associated with neurological disorders such as 
Guillain-Barré Syndrome (GBS)52. Sexual and perinatal transmission routes were observed 
in this virus; indeed the virus has been associated with the development of microcephaly in 
foetuses53,54.  
There is no cure or vaccine available to prevent ZIKV infection. Treatment is often 
supportive and mainly based on rest and avoiding dehydration. Nonsteroidal and anti-
inflammatory medicines should be discouraged to reduce the risk of the haemorrhagic 
syndrome reported with other flaviviruses, and antihistamines should be used to relieve 
pruritic rash55. 
Fourteen vaccine developers in France, USA, Brazil, India and Austria are currently working 
on the development of a vaccine against ZIKV56,57. Vaccines are already in the trial phase, 
although their commercialisation is not expected for some time yetb. Several potential 
therapeutic agents are also being evaluated58,59. More information about the origin, spread 
and characteristics of the virus is given in Chapter 5. 
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3.4 Tick-borne encephalitis virus 
 
Tick-borne encephalitis virus (TBEV) and West Nile virus (WNV) are flaviviruses considered 
to be pathogenic for humans. They have been present in Europe for a long time (Figure 
7)60,61.    
Three known subtypes of TBEV have been described so far: European or Western, Siberian 
and Far Eastern62. In Europe, TBEV has been reported in countries including Austria, the 
Czech Republic, Germany, Lithuania, Poland, Slovakia, and Sweden. More cases were 
reported in 2016 (1 900 cases) than in 2015 (1 258 cases)63. The first case of TBEV 
endemic transmission was recently reported in the Netherlands, demonstrating the spread 
of the disease to regions previously denoted as being TBEV-free64. TBEV transmission is 
mainly mediated by the vectors Ixodes ricinus and Ixodes persulcatus, although the thick 
Dermacentor reticulatus is increasingly reported as being a vector involved in the spread of 
the disease65. Dermacentor reticulatus is a vector of over 40 pathogenic agents, and is 
rapidly spreading in Europe. Two of its biological features are its high reproduction rate and 
the capacity to survive under unfavourable conditions. It is cold resistant and can live 
underwater for months66.  
TBEV is transmitted to the vector through 3 possible routes: i) co-feeding on infected hosts; 
ii) transtadial and transovarial transmission and iii) sexual transmission67. Indeed, ticks 
acquire the virus after feeding on small wild rodents (reservoir hosts) during the nymph and 
the adult stages, and the infected ticks can transfer the pathogen to other adult ticks 
through mating68. Transovarial transmission also occurs in ticks (also known as vertical 
transmission through the eggs to the larval stage), but this does not seem to play a central 
epidemiological role in TBEV transmission. TBEV can multiply on the tick vector, which 
thereby acts as a long-term reservoir for the virus. Humans and wild animals (including 
hares, roe deer, foxes, boar and birds) are the indicator hosts of TBEV. They are not able to 
transmit the virus back to the vectors, but they indirectly sustain the circulation of the virus, 
allowing the ticks to survive and reproduce. Seroprevalence in these vertebrates is also an 
indicator of TBEV within a geographical area69. Humans can be infected through the bite of 
an infected tick or by consuming unpasteurised products from infected goats, sheep, or 
cows. In Slovakia, the incidence of alimentary-acquired infections may account for nearly a 
quarter of the total reported cases63. Humans can develop a viral disease, the most common 
symptoms of which include fever, headache, nausea and vomiting. Severe headache and 
encephalitis, meningitis or meningoencephalitis occur in 20-30% of people affected by Tick-
borne encephalitis (TBE). Approximately 1-2% of people die from this infection70. The risk of 
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TBEV infection is linked to occupational exposure, outdoor leisure activities and travel to 
endemic regions. Climate change, including the growth of mean annual air temperature, is 
also expected to play a role in the geographic distribution and abundance of infected ticks 
and infection cases71,72.  
Vaccination against TBE is available, but public awareness of the disease and its prevention 
measures is low63,73. Cross-protection against other subtypes has been shown for 
vaccination based on the European subtype73,74. Vaccination against TBEV is recommended 
for people who live or work in, or travel to TBEV-risk areas.  
 
 
 
Figure 7. Global distribution of alerts of Tick-borne encephalitis virus (TBEV) in the past 6 
months (May-November 2017)                                                                                                                                         
The large circles indicate a country-level alert, while state, province and local alerts are 
indicated by the small circles. Marker colour reflects the importance of events at a particular 
location during a given time window. An event's degree of importance is based on the 
significance rating of the alert provided by HealthMap users.†† 
 
 
 
 
 
                                                          
†† Data source: http://www.healthmap.org/, last accessed on 13/11/2017. 
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3.5 West Nile virus 
 
West Nile virus (WNV) is globally widespread (Figure 8) and has been reported in Europe 
since the 1960s75. Nowadays, WNV outbreaks in Europe are irregular and temporally limited 
phenomena. In 2016, a total of 225 human cases of infections were reported in Europe, 
mostly in Romania and Italy76.  
WNV belongs to at least two main lineages (although four other WNV lineages have been 
also identified that show genetic differences to the major known ones)69. Lineage 1 is 
composed of WNV strains from Africa, Australia, Eastern Asia, Europe, North America and 
India77. Lineage 2 has been isolated in sub-Saharan Africa and Madagascar, but it has 
recently been reported in Hungary, Greece and Italy77. Lineage 2 strains were initially 
considered to be non-pathogenic in humans but, since 2008, these countries have reported 
human outbreaks caused by WNV lineage 2, resulting in neuroinvasive diseases that are 
sometimes fatal78,79. In Italy, in particular, WNV outbreaks occurred in Sardinia, in the Po 
river area and in Central Italy80-82.  
WNV has been detected in several genera of mosquitoes, which are the primary vectors for 
WNV transmission 69. In Europe, Culex pipiens, Culex perexiguus, and Culex modestus are 
important vector species, but Culex pipiens is the primary global WNV vector due to its 
propensity to feed on birds83. Wild birds are indeed considered the reservoir hosts for the 
virus, which is maintained in nature through a bird-mosquito cycle. Infected mosquitoes can 
transmit the virus to humans and animals such as horses, which are considered as dead-
end hosts for this infection because they cannot transmit the virus back to the vector. 
Infection in humans is mainly asymptomatic, and only 20-40% of the infected patients 
develop West Nile Fever (WNF), which is characterised by mild symptoms, including fever 
and headache84. Severe symptoms such as meningitis, encephalitis, and 
meningoencephalitis are reported in less than 1% of people affected, with nearly 10% 
mortality85.  
No human vaccines are currently available and there are no specific treatments for this 
infection. The best way to prevent WNV infection is to reduce exposure to mosquito bites by 
wearing clothing that covers the arms and legs, control the spread of the vector by reducing 
the number of water-filled containers that provide breeding habitats, and use insect 
repellents. 
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Figure 8. Global distribution of alerts of West Nile virus (WNV) in the past 6 months (May-
November 2017) 
The large circles indicate a country-level alert, while state, province and local alerts are 
indicated by the small circles. Marker colour reflects the importance of events at a particular 
location during a given time window. An event's degree of importance is based on the 
significance rating of the alert provided by HealthMap users.‡‡ 
 
 
 
 
 
 
 
                                                          
‡‡ Data source: http://www.healthmap.org/, last accessed on 13/11/2017. 
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4 Clinical signs and virus detection  
4.1 Clinical signs 
Table 2 summarises the symptomatic profiles of the emerging Dengue (DENV), 
Chikungunya (CHIKV), Zika (ZIKV), Tick-borne encephalitis (TBEV) and West Nile (WNV) 
viruses. Figure 9 shows the number of cases for each virus reported in European countries 
and the total number of cases in the 31 countries in the European Economic Area. Note that 
the number of reported cases refer to different time periods for the different viruses, based 
on the data in the Surveillance Atlas of Infectious Diseases of the European Centre for 
Disease Prevention and Control (ECDC). The reported cases may be associated with travel, 
local transmission, or unknown causes. The data clearly point out the difference in 
transmission dynamics between TBEV and the other arboviruses. The reported cases of 
DENV, CHIKV, ZIKV and WNV are mostly associated with travel, while TBEV is principally 
reported to have local causes. This means that global interconnections provide the perfect 
conditions for the spread of DENV, CHIKV, ZIKV and WNV.  
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Table 2. Emerging viruses and their symptomatic profiles 
 
 
 
 
 
 
 
 
 
 
 
 
Virus Symptoms Comments 
Dengue 
High temperature, 
headache, joint pain, 
myalgia/arthralgia, skin 
rash, leukopenia, 
thrombocytopenia 
Symptoms last for 3 to 7 
days 
Dengue  
(re-infection, DHF) 
Severe thrombocytopenia, 
plasma leakage, 
haemorrhage 
Occurs by multiple DENV 
serotypes infection 
Chikungunya 
Fever, headache, skin rash, 
thrombocytopenia and 
leukopenia, acute arthritis, 
severe joint pains, Guillain-
Barré Syndrome 
Low mortality rate 
Zika 
Fever, joint pain, skin rash, 
conjunctivitis, Guillain-Barré 
Syndrome, microcephaly 
80% of asymptomatic 
infections. 
Transmission also by sexual 
and perinatal routes 
West Nile 
Fever, headache, joint 
pains, vomiting, body aches,  
muscle weakness 
Low mortality rate 
Tick-borne encephalitis 
Fever, headache, nausea, 
vomiting, fatigue, malaise, 
myalgia, gastrointestinal 
symptoms, leukocytopenia 
70-95% of asymptomatic 
infections. 
Low mortality rate 
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Figure 9. Number of reported cases in Europe of Chikungunya virus (CHIKV), Dengue fever 
virus (DENV), Zika virus (ZIKV), Tick-borne encephalitis virus (TBEV), and West Nile virus 
(WNV)§§  
 
                                                          
§§ Data source: https://ecdc.europa.eu/en/surveillance-and-disease-data, last accessed on 1/12/2017. Dataset 
provided by ECDC based on data provided by WHO and Ministries of Health of the affected countries. The views 
and opinions of the authors expressed herein do not necessarily state or reflect those of the ECDC. The accuracy of 
the authors' statistical analysis and the findings they report are not the responsibility of the ECDC. The ECDC is not 
responsible for conclusions or opinions drawn from the data provided, or for the correctness of the data, data 
management, data merging and data collation after provision of the data. The ECDC shall not be held liable for 
improper or incorrect use of the data. 
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4.2 Virus detection 
 
The detection arboviruses such as Zika (ZIKV), Dengue (DENV), Chikungunya (CHIKV), 
West Nile (WNV) and Tick-borne encephalitis (TBEV) viruses is mainly based on Enzyme-
Linked Immunosorbent Assays (ELISA) or quantitative Polymerase Chain Reactions (qPCR) 
(Figure 10)86-89. Quantitative PCR is a technique used to quantify the expression of ZIKV-
associated genes, while ELISA analyses are performed to identify virus-specific 
immunoglobulin and neutralising antibodies90,91. Quantitative PCR detection is specific to 
ZIKV, although it can generate false negatives due to virus mutation or the presence of 
amplification inhibitors92. Specific serological tests aimed at identifying immunoglobulins and 
antibodies may present cross-reactivity between ZIKV and other flaviviruses (i.e. DENV and 
Yellow Fever virus), which can lead to false positive results and misdiagnoses90. However, 
the detection of virus-specific antibodies does not always indicate an active infection. 
Positive results may be due to previous exposure to the virus or to a past vaccination. This 
means that these results could be difficult to interpret.  
 
Figure 10. Techniques to detect arboviruses (Source: JRC) 
The Enzyme-Linked Immunosorbent Assay (ELISA) and the quantitative Polymerase Chain 
Reaction (qPCR) are the techniques most frequently used to detect arboviruses in infected 
samples. 
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5 Zika: an emerging virus 
5.1 Origin and spread of Zika virus 
 
Zika virus (ZIKV) was first described in the 1940s and took the name from the forest where 
it was found, in Uganda93. The virus was isolated for the first time from Aedes africanus 
mosquitoes during a study of monkey resistance to Yellow Fever virus (YFV) and it was later 
isolated from Aedes aegypti in Malaysia93,94. At present, thirteen species of mosquito have 
already been found to carry ZIKV in nature, which corroborates the potential for more 
mosquito species to become vectors of this disease95. Even though ZIKV is especially 
transmitted to humans by Aedes aegypti, Aedes albopictus mosquitoes have also been 
implicated in outbreaks of the virus55,96. Aedes albopictus, better known as the tiger 
mosquito, has a wide distribution in temperate zones, beyond the tropical and subtropical 
regions to which Aedes aegypti mosquitoes are confined. At present, the distribution of 
Aedes albopictus in different areas such as Europe and America makes the local spread of 
ZIKV a serious concern. Major recommendations are addressed to individuals that are 
considering travel to places where ZIKV is present, because they need to take protective 
measures to avoid mosquito bites and prevent ZIKV transmission after returning to their 
countriesa.  
After its detection in 1947, the first documented outbreak of a ZIKV infection was reported 
in Yap Island (Micronesia) many years later, in 200797. Since then, the virus spread to 
French Polynesia where it caused more than 29 000 infection cases from October 2013 to 
February 2014, infecting about 11% of the population98. From there, the virus was 
introduced into Brazil. The Brazilian Ministry of Health estimated that between 0.4 and 1.3 
million people were infected in 2015 and, as of 29 March 2016, all Brazilian states reported 
ongoing cases of Zika (ZIK) infections99. Since the outbreak, more than seventy territories 
worldwide have confirmed autochthonous cases of ZIK (Figure 11)99-101. To these must be 
added reports of episodes of non-vector-borne transmission in countries such as France, 
Italy and Portugal (Madeira)99. In these countries, virus transmission occurred through 
routes that may include sexual or perinatal transmission.  
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Figure 11. Global distribution of alerts of Zika virus (ZIKV) in the past 6 months (May-
November 2017) 
The large circles indicate a country-level alert, while state, province and local alerts are 
indicated by the small circles. Marker colour reflects the importance of events at a particular 
location during a given time window. An event's degree of importance is based on the 
significance rating of the alert provided by HealthMap users.*** 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
                                                          
*** Data source: http://www.healthmap.org/, last accessed on 13/11/2017. 
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5.2 Clinical signs, transmission and relationship with neurological 
disorders 
 
When the first Zika virus (ZIKV) epidemic was reported in the Federal State of Micronesia in 
2007, it was assumed to be related to Dengue virus (DENV). Although ZIKV is more often 
associated with conjunctivitis, there are no other features to distinguish between these two 
infections51. In addition, asymptomatic cases of ZIKV are estimated at 80%, making its 
diagnosis and prevention even more difficult97.ZIKV has been associated with serious 
neurological disorders such as Guillain-Barré Syndrome (GBS) and microcephaly52,54,102,103. 
Mutations in ZIKV have recently been described and may be associated with the increased 
severity of the symptoms reported in the latest outbreaks104.  
 
In suburban and urban settings, ZIKV is primarily transmitted through the bite of infected 
mosquitoes from the Aedes genus in a human–mosquito–human transmission cycle (Figure 
12). Other routes of transmission have been investigated, and many reports now indicate 
that ZIKV can be transmitted through perinatal and sexual transmission (Figure 12)53,105-107. 
Recognising the impact of sexual transmission, the World Health Organization (WHO) has 
released interim guidance regarding its prevention. By March 2017, 2 130 Europeans were 
reported to have travel-associated ZIKV infections, of which 20 were infected through 
sexual transmission108. ZIKV was isolated in blood, urine, saliva, cerebrospinal fluid, 
amniotic fluid and breast milk, but further investigation is needed to understand if these 
incidences could be considered other forms of contagion51. Transfusion-transmissible 
infections have also been suggested109,110.  
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Figure 12. Human-mosquito-human transmission cycle (Source: JRC) 
In suburban and urban settings, the transmission of Zika virus (ZIKV) occurs primarily 
through a human–mosquito–human transmission cycle. The upper panel (Figure 12A) 
describes the main route of transmission where the virus can pass from humans to humans 
by the bites of infected Aedes mosquitoes. Figure 12B shows the other routes of ZIKV 
transmission, including sexual and perinatal transmission. ZIKV may also be spread through 
blood transfusion.    
 
An association between ZIKV and the neurological disorder GBS was first noted during the 
large outbreak that occurred in French Polynesia in 2013111. GBS is a severe acute paralytic 
neuropathy that affects the peripheral nerve myelin. It is characterised by muscle weakness 
and paralysis (Figure 13)112. This neurological disorder is more common in adults 
(particularly in males), and is usually preceded by an infection that prompts an autoimmune 
response against peripheral nerve tissue. Since October 2015, GBS has been detected at an 
increasing rate in several countries, including Brazil, Colombia, the Dominican Republic and 
Venezuela. In each country, at least one GBS case was confirmed as being associated with 
ZIKV infection. WHO Emergency Committee on Zika has agreed that ZIKV is one of the 
causes of GBS, although other viruses have been also associated with this disease52,55,99,113. 
In September 2015, researchers reported an increase in the number of cases of neonates 
born with microcephaly in north-eastern Brazil, and subsequently also in the south-eastern 
part of the country. Different studies have analysed the association between ZIKV and 
microcephaly after the first reported cases of perinatal transmission. Microcephaly and/or 
Central Nervous System (CNS) malformation episodes have since been documented in 
many other countries where ZIKV was also circulating (Figure 13)99,114. Microcephaly is 
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characterised by incomplete brain development, which results in some degree of mental 
retardation. At present there is no cure for ZIKV infection115. ZIKV has been identified in the 
amniotic liquid of pregnant women and in body tissues of the foetal brain, the brain tissues 
of newborns with microcephaly, and placental tissues of miscarriages115,116-119.  
The neurotropism of ZIKV was first discovered in infected mice, where the virus was 
isolated from brain tissues and seemed to cause a decrease in brain volume during the 
embryonic stage120-121-123. In addition, a laboratory study confirmed that ZIKV has the 
capacity to target neural cells by efficiently infecting Human Cortical Neural Progenitor Cells 
(hNPCs) and attenuating their growth124. An epidemiological study performed on a group of 
Brazilian women suggests that ZIKV infection during pregnancy appears to be related not 
only to microcephaly but also to other grave severe neurological outcomes, including 
cerebral calcifications, intrauterine growth restriction and abnormal umbilical artery flow119.  
Currently, substantial evidence suggests a causal link between ZIKV and foetal brain 
anomalies, including microcephaly, especially during the first gestational trimester. 
However, the mechanism by which mothers can transmit the virus to their babies and the 
foetus neuronal alteration are still unknown. 
It is recommended that people, particularly pregnant women, avoid travelling to areas 
where ZIKV is circulating. Individuals who live in ZIKV-infected zones should limit mosquito 
bites by using skin repellents, bed nets and staying in places with air conditioning to keep 
mosquitoes outside. In the absence of specific treatments, protection against mosquito 
exposure is the only prevention method available to reduce the impact of the infection.  
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 Figure 13. Zika virus (ZIKV) and associated neurological disorders (Source: JRC) 
(A) Transmission of Zika virus (ZIKV) from infected persons to healthy persons can induce 
the Guillain-Barré Syndrome, a neurological disorder characterised by a progressive 
inflammation of the peripheral nerves. (B) The neonatal transmission of ZIKV from women 
to newborns is associated with a negative impact on infants’ health. Neurological disorders 
observed in newborns, including microcephaly, tested positive for ZIKV. Other central 
nervous system malformations have been also suggested.  
 
 
 
5.3 Zika virus and media misinformation 
 
The outbreak of Zika virus (ZIKV) has been closely followed by the media. Information 
about ZIKV is readily available on the internet, but is often not supported by reliable 
scientific references. In Table 3 we have compared a list of relevant media news items with 
scientific findings, in order to give an overview of the veracity or falsity of news released to 
the public.    
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Table 3. Information on the outbreak of Zika virus (ZIKV): “media versus science” – 
comparison of media information and scientific knowledge, based on peer-reviewed 
publications 
Media news Peer-reviewed papers  
The spread of Zika virus (ZIKV) may be 
associated with the El Niño regime, increasing 
global temperatures and global travelc. 
Malone et al. (2016) has raised the 
hypothesis that the El Niño weather 
pattern may have favoured the spread of 
mosquitoes in many areas, coupled with 
cargo and cruise shipping routes, 
indicating the potential for the additional 
spread of Zika virus (ZIKV) during 2016 
to many regions of the Americas125.                                       
The information spread by the media on 
this topic was correct. 
The introduction of Zika virus (ZIKV) into Brazil 
is related to the World Cup held in Brazil in 
2014d. 
Musso (2015) stated that Zika virus 
(ZIKV) strain found in the Brazilian 
outbreak is correlated with the 
Polynesian one. The timing of the Va’a 
World Sprint Championships in Rio de 
Janeiro, in which Polynesia competed, fits 
with the beginning of the outbreak126. 
Pacific countries infected with ZIKV did 
not compete in the 2014 World Cup 
soccer competition. 
The information spread by the media on 
this topic was incorrect. 
The United States of America wants to start 
vaccine trials on humans by the end of 2016c. 
In the USA, Human vaccine trials started in 
August 2016e. 
Fourteen vaccine developers in countries 
including France, the USA, Brazil, India 
and Austria are currently working on the 
development of a vaccine against Zika 
virus (ZIKV), but a timeline for its 
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distribution cannot be predicted56. 
The National Institute of Allergy and 
Infectious Diseases has established 
strategies to test the vaccine 
candidates127. Preliminary trials started in 
August 2016b,f. 
The information spread by the media on 
this topic was correct. 
A possible association of Zika virus (ZIKV) 
infection with birth malformations and 
neurological syndromes has been publicised, 
stating that doctors were able to isolate the 
virus in some children suffering from 
microcephaly. The Centers for Disease Control 
and Prevention (CDC) reported that “some 
samples” from children born with microcephaly 
tested positive for ZIKV, while “several” did 
notd. 
A link was established between ZIKV and 
microcephalyg. 
Different scientific papers supported the 
hypothesis that the virus could be 
transmitted from a pregnant woman to 
the newborn, but there are not sufficient 
data to confirm that Zika virus (ZIKV) is 
the causative agent of 
microcephaly102,114-119,128. Nevertheless, 
World Health Organization (WHO) has 
accepted the correlation between the two 
eventsh.                                            
The information spread by the media on 
this topic was correct. 
Infection of the foetus is believed to have 
higher prevalence during the first gestation 
semesterc. 
A scientific study has provided strong 
statistical support for the association 
between Zika virus (ZIKV) infection and 
microcephaly, by establishing that the 
period of risk was likely to include the 
ﬁrst trimester of pregnancy. Further 
analyses are necessary to prove this 
relationship129.                              
The information spread by the media on 
this topic was not fully correct. 
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Four out of five infected people show no 
symptomsc. 
It is estimated that 80% of Zika virus 
(ZIKV) infections are asymptomatic97. 
The information spread by the media on 
this topic was correct. 
Transmission is mainly through mosquito bites, 
although sexual transmission has also been 
reportedi,j. Zika virus (ZIKV) can also be 
transmitted through blood transfusionsk.  
Zika virus (ZIKV) is primarily transmitted 
to people through the bite of an infected 
mosquito. Other routes of transmission 
that have been proposed include sexual 
and perinatal transmission. ZIKV may 
also be spread through blood 
transfusion105.  
The information spread by the media on 
this topic was not fully correct. 
Genetically modified mosquitoes could be the 
cause of Zika virus (ZIKV) outbreakl,m. 
The potential use of genetically modified 
mosquitoes for pest control has been 
demonstrated to work in containing the 
disease, although it requires that a great 
number of mosquitoes be introduced into 
the environment130. There is no evidence 
that genetically modified mosquitoes 
cause Zikan. Other containment methods 
have been attempted, such as using 
molecular interference (iRNA) to induce 
mosquito death or infection of wild 
mosquitoes with a bacteria that can 
reduce the transmission efficacy131-132.  
The information spread by the media on 
this topic was not correct. 
The pandemic potential of this virus is high, 
given global sport activities, such as the 
Olympic games, and the increase in global 
travelc. 
By 4 April 2017, the European Centre for 
Disease Prevention and Control (ECDC) 
had reported 2 142 imported infection 
cases in European citizens returning from 
affected countries100. 
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The information spread by the media on 
this topic was correct. 
Labs will soon have a test that can detect all 
three viruses borne by the Aedes mosquito – 
Dengue (DENV), Chikungunya (CHIKV) and 
Zika (ZIKV) viruses. The test, however, will be 
effective only during the initial infection period 
of five dayso. 
Immunoassays based on Ig detection are 
available for Dengue (DENV) and Zika 
(ZIKV) viruses, but the cross-reactivity of 
the test is too high to be able to 
discriminate the causative virus90,133. The 
Centers for Disease Control and 
Prevention (CDC) released a qPCR-based 
emergency test for the detection of ZIKV, 
DENV and Chikungunya virus (CHIKV)p.  
The information spread by the media on 
this topic was correct. 
Doctors’ hypothesize that pesticides used for 
pest control in Brazil could be responsible for 
foetus malformations that had recently been 
linked to Zika virus (ZIKV)q,r,s. 
Based on a European Food Safety 
Authority (EFSA) report, pyriproxyfen 
has low toxicity effects on mammals, 
including humans134. No reliable scientific 
sources were found to correlate 
pyriproxyphen with microcephaly. 
Similarly, malathaion was found to have 
low toxicity by oral route, no acute 
toxicity via dermal exposure and 
potential genotoxicity135. 
The information spread by the media on 
this topic was not scientifically 
supported. 
 
Further information on misleading media news can be found on the World Health 
Organization (WHO) websitet. 
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6 Mosquito control strategies 
 
In ecosystems, mosquito abundance is controlled by natural predators such as birds and 
fish, and by natural events such as hurricanes, droughts and cold spells. Urban areas 
provide a positive breeding environment for mosquitoes, given that natural predation is not 
significant and there is high availability of breeding sites. In these situations, the risk of 
infection is higher and human health is threatened. Mosquito-control strategies are 
therefore needed. There are currently five main methods of mosquito control i) 
extermination through the use of insecticides; ii) biomass reduction through the use of 
traps; iii) reduction of biomass through genetic modifications; iv) land reclamation in order 
to fight or prevent the spread of mosquitoes; v) control of water spaces (places) where the 
eggs and larvae can survive. 
Most common insecticides used for mosquito control are chemical-based compounds that 
are applied by nebulisation/fumigation. Unfortunately, they raise (eco) toxicological issues, 
as with the extensive use of Dichlorodiphenyltrichloroethane (DDT)136. The use of 
insecticides was found to be very successful in eradicating diseases such as malaria from 
many regions136. Most recently, in Brazil, attempts to control the spread of Zika virus (ZIKV) 
have been made through mosquito-eradication campaigns using pesticides such as 
pyriproxyfen and malathion. Pyriproxyfen is an insecticide that is used for pest control on 
tomato and cotton crops, as it suppresses embryogenesis and inhibits metamorphosis and 
reproduction. The media recently speculated about its effects on the incidence of 
microcephaly casesq. Based on a European Food Safety Authority (EFSA) report, this 
chemical is considered to be very toxic to aquatic organisms, but no major effects were 
found for other organisms, including humans134. Nevertheless, it must be noted that human 
risk was not evaluated due to the low toxicity profile found for model mammals. Malathion, 
another pest control agent, was shown to have low toxicity for rats through oral exposure 
and no acute toxicity via dermal or inhalation exposure137. However, there is strong 
evidence that malathion may be an endocrine disruptor and have genotoxic properties138. 
This chemical is currently under revision in Europe. 
Attempts at biological control based on biocides have been reported. Bacillus thuringiensis 
var. israelensis (Bti), a group of toxin-producing bacteria, has been used for mosquito 
control. This bacteria produce toxin crystals that act as insecticides and have no toxicity for 
humans. Unfortunately, the use of Bti was shown to have an indirect impact on non-target 
organisms; for example, it was found to reduce bird breeding behaviour as a result of the 
decrease in food availability139. 
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Sterile male mosquitoes have been introduced into the field in order to reduce offspring. 
The potential of these organisms for biomass control has been demonstrated, although a 
great number of mosquitoes must be introduced in the environment, which limits the size of 
the treatable area130. Interference RNA (iRNA) technology is also promising as it is target-
specific and can be used on fumigation campaigns, in the same way as insecticides. The 
technology works by disrupting the expression of any gene of interest in a specific manner 
by using double-stranded RNA (dsRNA). The dsRNA targeting key genes involved in 
apoptosis can be topically applied to mosquitoes and used as molecular insecticides to 
control their spread. However, mass production of iRNA products is currently not possible, 
and specific formulations should be developed to ensure the efficient delivery of the dsRNA 
into mosquitoes131. 
At the moment, mosquito traps and nets are the safest and most available method of 
mosquito control. Mosquito traps, for adult stages, mimic the scent of warm-blooded 
animals, thereby attracting female mosquitoes. This is an effective pest-control mechanism 
for relatively small areas, but it has limited success in open field areas. The same applies for 
oviposition traps, which are artificial breeding containers impregnated with insecticides. 
Oviposition traps are attractive to gravid mosquito females which become compromised 
upon contact with the insecticide. There are other effective insecticide products that are safe 
for the environment (e.g. vegetable oils). In habitational areas, the use of traps together 
with the active reduction of potential breeding sites (such as fountains, ponds or water-filled 
containers) can effectively reduce mosquito abundance.  
Despite many attempts to reduce the negative effects of mosquitoes on humans, it would be 
unwise to remove them completely from the ecosystem as they are part of the food chain. 
For example, mosquitos are fed on by bird species living in the Arctic tundra, and are also 
part of the diet of dragonflies, spiders, frogs and fish140. In the absence of mosquitoes, 
many plants would lose their pollinators140. Mosquitoes are therefore part of the food web 
for some species, and permanently wiping out these insects could have adverse effects in 
nature, and consequently on humans.  
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